DYNE THERAPEUTICS INC (DYN)
US26818M1080 - Common Stock
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dyne Therapeutics (NASDAQ:DYN) just reported results for the first quarter of 2...
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM,...
Notable Friday Option Activity: COIN, SIBN, DYN
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing...
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Dyne Therapeutics Announces CEO Transition
Dyne Therapeutics Announces CEO Transition
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 ...
First Week of May 17th Options Trading For Dyne Therapeutics (DYN)
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing...
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dyne Therapeutics (NASDAQ:DYN) just reported results for the fourth quarter of ...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise...
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -
Dyne Therapeutics to Present at February Investor Conferences
Dyne Therapeutics to Present at February Investor Conferences
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing...
Dyne Therapeutics stock jumps amid report of takeover interest
Dyne Therapeutics (DYN) surges 8.4% as the company explores strategic options, including a potential sale or partnership, following takeover interest.
Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest
Dyne Therapeutics Inc., a developer of drugs to treat muscle diseases, is considering options after receiving takeover interest from larger pharmaceutical companies, people with knowledge of the matter said.
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.
First Week of September 20th Options Trading For Dyne Therapeutics (DYN)
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing...
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing...